Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decanol SCHEMBL11043200 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| Decanol SCHEMBL10945703 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| Dodecanol SCHEMBL29212179 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| Hexane SCHEMBL5393961 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| SCHEMBL29017540 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| Cetyl Alcohol SCHEMBL27937278 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| Heptane SCHEMBL1238729 | 0.98 | DGKA (0.64) | DGKACYP1A2PAMLMNAKDM4E | |
| 1-Hexanol SCHEMBL1863211 | 0.94 | DGKA (0.59) | DGKACYP1A2PAMLMNAKDM4E | |
| Butyl Alcohol SCHEMBL11099381 | 0.94 | DGKA (0.59) | DGKACYP1A2PAMLMNAKDM4E | |
| Ethylene Glycol SCHEMBL4292535 | 0.94 | DGKA (0.63) | DGKACYP1A2PAMLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8841425-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8435528-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2363390-A1 | DERIVED LACTAM FROM D3 VITAMIN | Teijin Pharma Limited (JP) | 2011-09-07 | — | — | EP | disclosed |
| US-20110207944-A1 | VITAMIN D3 LACTAM DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7851432-B2 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1838715-B1 | METHOD FOR THE PREPARATION OF MAYTANSINOID ESTERS | IMMUNOGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009080200-A1 | NOVEL SULPHOXIMIDE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-1997042169-A2 | BENZOPHENONE HYDRAZONE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0482084-B1 | (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES | UPJOHN CO (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5491236-A | NERVOUS SYTEM DISORDERS | THE UPJOHN COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1991000856-A2 | (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | SPR, SDAD1, ARRB1 | DGKA 3553/4885CYP1A2 3053/4885PAM 642/4885 |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | DGKA 2293/4885CYP1A2 3419/4885PAM 113/4885 |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | PTMS, CYP4A11, CYP11B1 | DGKA 1960/4885CYP1A2 280/4885PAM 394/4885 |
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | DGKA 2759/4885CYP1A2 4418/4885PAM 524/4885 |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | DGKA 3294/4885CYP1A2 3498/4885PAM 819/4885 |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | DGKA 2232/4885CYP1A2 3253/4885PAM 614/4885 |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | DGKA 3294/4885CYP1A2 3498/4885PAM 819/4885 |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | DGKA 2232/4885CYP1A2 3253/4885PAM 614/4885 |
| US-20110207944-A1 | VITAMIN D3 LACTAM DERIVATIVE | VDR, CYP24A1, CYP2R1 | DGKA 2655/4885CYP1A2 327/4885PAM 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.